Curis

Curis Operating Expenses

The Total Operating Expenses of Curis (CRIS) as of Nov 19, 2026 is 42.30 M USD. In the previous year, Total Operating Expenses was 55.35 M USD — a change of -23.58% (lower).

Operating Expenses

42.30 MUSD

YoY

-23.58%

Last updated:

Total Operating Expenses of Curis is 2025 42.30 M USD. Total Operating Expenses of Curis was 2024 55.35 M USD. It decreases by -23.58% lower compared to the previous year.

The Curis Operating Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Expenses
Date
Operating Expenses
Jan 1, 2018
39.20 M USD
Jan 1, 2019
33.86 M USD
Jan 1, 2020
35.20 M USD
Jan 1, 2021
52.18 M USD
Jan 1, 2022
62.93 M USD
Jan 1, 2023
58.14 M USD
Jan 1, 2024
55.35 M USD
Jan 1, 2025
42.30 M USD
The Curis Operating Expenses history
YEAROperating ExpensesYoY
42.30 MUSD-23.58%
55.35 MUSD-4.80%
58.14 MUSD-7.60%
62.93 MUSD+20.59%
52.18 MUSD+48.25%
35.20 MUSD+3.96%
33.86 MUSD-13.63%
39.20 MUSD-33.74%
59.16 MUSD+25.40%
47.18 MUSD+19.12%
39.61 MUSD+56.14%
25.37 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Curis Stock analysis

What does Curis do? Curis Inc generates revenue primarily through the development and potential commercialization of its therapeutic drug candidates in the biotechnology sector. The company focuses on oncology treatments, with its lead candidate Emavusertib targeting IRAK4 kinase inhibition for cancer therapy. Other key products include Erivedge, which inhibits the Hedgehog signaling pathway, and additional candidates like CI-8993, Fimepinostat, CA-170, and CA-327, targeting various cancer-related pathways. The firm conducts R&D internally and via strategic collaborations, aiming to advance these drug candidates toward clinical and commercial stages. Curis Inc's primary buyers are pharmaceutical companies and healthcare institutions seeking innovative cancer treatments. The company's pipeline includes orally available small molecule drugs and monoclonal antibodies designed for targeted cancer therapies. Emavusertib, Erivedge, and CA-170 represent the core product segments, with CA-170 specifically targeting VISTA and PDL1 immune checkpoint proteins. Strategic collaborations support the development of these therapeutics, aligning with the company's focus on oncology drug discovery and development. The company's revenue streams are tied to the progression of its drug candidates through clinical trials and potential partnerships. Emavusertib and Erivedge are in clinical stages, with CA-170 also advancing in development. Curis Inc's business model emphasizes internal R&D alongside strategic alliances to accelerate the development of its pipeline, ensuring that its products reach the market for cancer treatment applications. Curis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Curis stock

Total Operating Expenses of Curis is 42.30 M USD in 2025.

Total Operating Expenses of Curis changed from 55.35 M USD to 42.30 M USD, representing a -23.58% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Operating Expenses Curis since 2006 – with annual values, charts, and detailed analysis.

Operating expenses are the costs incurred in the normal course of business operations, including COGS, SG&A, R&D, and depreciation.

Total Operating Expenses's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Operating Expenses's Curis historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Curis

All Key Metrics — Curis